Stay updated with breaking news from Double Blind Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
Sara A. Hurvitz, MD, presents data from the phase 3 HER2CLIMB-02 study investigating tucatinib and trastuzumab emtansine in patients with previously treated HER2+ metastatic breast cancer.
Highlights: Participant screening closed for ATH434-201 Phase 2 studyIndependent Data Monitoring Committee recommended the ATH434-201 Phase 2 study continue as plannedReceived A$4.74M cash refund...
BUSINESS SECTION Overview Company Overview We are a clinical-stage biopharmaceutical company focused on developing...
STOCKHOLM, April 3, 2023 /PRNewswire/ -- BioArctic AB and its partner Eisai has presented new findings on lecanemab , an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's... | April 3, 2023